全球人造血液市場（~2028）

全球人造血液市場規模預計將從 2022 年的 2390 萬美元和 2023 年的 2610 萬美元成長到 2028 年的 4050 萬美元，預測期內年複合成長率為 9.2%。

本報告調查了全球人造血液市場，並提供了市場概況、市場影響因素和市場機會分析、市場規模趨勢和預測、各個細分市場和地區的詳細分析、產品分析以及技術和專利趨勢、競爭形勢、概況主要企業等

目錄

第1章 簡介

第2章 總結/要點

第3章 市場概況

• 人類血液問題
• 人造血液的新需求
• 人造血液：有助於解決感染疾病風險
• 人造血液：減輕捐血者血液供應負擔
• 人造血液：需要應對血液系統的意外需求
• 開發人造血液製品的障礙
• 人造血液的理想特性
• 人造血液優於人類血液
• 用途
• 外科手術
• 緊急復甦
• 短期使用
• 案例比人血更有效
• 因宗教信仰而拒絕
• 人造血液開發的課題

第4章 市場動態

• 促進因素
• 輸血需求增加
• 與輸血相關的風險和課題
• 血液供應不足
• 障礙
• 產品核可率低
• 產品驗收
• 產品定價
• 機會
• COVID-19 的影響

第5章 人造血液：按來源分類

• 人造血液是由人類血液研製而成
• 由動物血液研製而成的人造血液
• 利用基因重組技術開發的人造血液
• 表面修飾血紅蛋白
• 交聯血紅蛋白
• 聚合血紅蛋白
• 封裝
• 基因工程重組血紅蛋白
• 天然血紅蛋白

第6章 人造血液：按類型

• 全氟化碳乳液
• 全氟化碳的一般性質
• 乳液選擇
• 全氟化碳乳液的歷史發展
• 第一代PFC
• 第二代PFC
• 第三代PFC
• 血紅蛋白氧載體 (HBOC)
• HBOC的一般特徵
• 歷史事件：血紅蛋白溶液

第7章 市場預估

• 人造血液的潛在市場
• 人造血液市場：按來源分類
• 血液（動物/人）
• 合成聚合物
• 人造血液市場：按類型
• 血紅蛋白氧載體
• 全氟化碳產品
• 人造血液市場：按地區
• 北美
• 歐洲
• 新興市場

第8章 新技術和發展

• 概述
• 新技術
• 奈米膠囊技術
• 幹細胞
• 其他正在進行的血液替代品研究

第9章 產品分析

• 產品安全
• 產品功效
• 產品成本
• 法律影響
• 部分在研產品的產品分析
• Hemopure
• HemO2life
• HemoTech
• NanO2 (DDFPe)
• Sanguinate
• Vidaphor
• 臨床試驗
• 一些處於臨床前和早期 I 期階段的產品的描述
• ErythroMer
• Hemoglobin vesicles
• OxyVita
• OxyBridge

第10章 專利分析

• FDA法規
• FDA 良好生產規範和報告
• 專利分析

第11章競爭資訊

• 戰略發展
• 競爭分析

第12章公司簡介

• AURUM BIOSCIENCES
• ERYPHARM
• HEMOGLOBIN OXYGEN THERAPEUTICS LLC.
• HEMARINA
• KALOCYTE INC.
• NANO SANGUIS SA
• NUVOX PHARMA LLC.
• PROLONG PHARMACEUTICALS, LLC
• RED C BIOTECH
• VIRTECH BIO

Highlights:

The global artificial blood market reached $23.9 million in 2022, should reach $26.1 million by 2023 and $40.5 million by 2028 with a compound annual growth rate (CAGR) of 9.2% during the forecast period of 2023-2028.

Report Scope:

The scope of this study encompasses an investigation of the global market for artificial blood, focusing on various important aspects of the market, such as research and development, clinical trial outcomes, approval status, and the potential commercial demand for artificial blood products. The report includes a discussion of artificial oxygen carrier products. BCC Research analyzes each market segment and provides a forecast for six years. The current report analyzes the market's drivers, challenges, and opportunities. The report also covers market projections for 2028 and the market analysis for key market players. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides information on emerging technologies, the impact of COVID-19, product analysis, deals, and investment outlook.

Report Includes:

• 41 tables
• An overview of the global markets for artificial blood
• Estimation of market size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Highlights of the market potential and characterization of artificial blood market by product, application, and region
• Examination of the key drivers and constraints that will shape the market and discussion on the upcoming market opportunities and areas of focus to forecast the market into various segments and sub-segments
• Coverage of recent advances, emerging technologies, and developments of the industry
• Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry
• Company profiles of major players within the industry, including Hemarina, VirTechBio, and NuvOx Pharma

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• What's New in This Update?
• Methodology
• Information Sources
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Market Overview

Chapter 3 Market Overview

• Introduction
• Is There a Problem with Human Blood?
• Emerging Needs for Artificial Blood
• Artificial Blood Will Be Useful in Dealing with the Risks of Infection
• Artificial Blood Will Help to Decrease the Load on the Donor Blood Supply
• Artificial Blood Is Needed to Deal with Unexpected Demands on the Blood System
• Hurdles in the Development of Artificial Blood Products
• Ideal Characteristics of Artificial Blood
• Artificial Blood Over Human Blood
• Applications
• Surgeries
• Emergency Resuscitation
• For Short-term Use
• Where More Effective Than Human Blood
• Rejections Due to Religious Beliefs
• Challenges in Artificial Blood Development

Chapter 4 Market Dynamics

• Drivers
• Increasing Demand for Blood Transfusions
• Risks and Challenges Associated with Blood Transfusions
• Shortage of Blood Supply
• Barriers
• Low Rate of Product Approvals
• Product Acceptance
• Product Pricing
• Opportunities
• Impact of COVID-19

Chapter 5 Artificial Blood by Source

• Introduction
• Artificial Blood Developed from Human Blood
• Artificial Blood Developed from Animal Blood
• Artificial Blood Developed Using Recombinant Technology
• Surface Modified Hemoglobin
• Cross-Linked Hemoglobin
• Polymerized Hemoglobin
• Encapsulation
• Genetically Engineered Recombinant Hemoglobin
• Natural Hemoglobin

Chapter 6 Artificial Blood by Type

• Introduction
• Perfluorocarbon Emulsions
• General Characteristics of Perfluorocarbons
• Emulsion Selection
• Historical Developments of Perfluorocarbon Emulsions
• First Generation of PFCs
• Second Generation of PFCs
• Third Generation of PFCs
• Hemoglobin-based Oxygen Carriers
• General Characteristics of HBOCs
• Historical Events: Hemoglobin Solutions

Chapter 7 Market Estimation

• Introduction
• Potential Market for Artificial Blood
• Artificial Blood Market, by Source
• Blood (Animal/Human)
• Synthetic Polymers
• Artificial Blood Market, by Type
• Hemoglobin-based Oxygen Carriers
• Perfluorocarbon-based Products
• Artificial Blood Market, by Region
• North America
• Europe
• Emerging Markets

Chapter 8 Emerging Technologies and Developments

• Overview
• Emerging Technologies
• Nanocapsule Technology
• Stem Cells
• Other Ongoing Research for Blood Substitutes

Chapter 9 Product Analysis

• Introduction
• Product Safety
• Product Effectiveness
• Product Cost
• Legal Implications
• Product Analysis of Some of the Products Under Development
• Hemopure
• HemO2life
• HemoTech
• NanO2 (DDFPe)
• Sanguinate
• Vidaphor
• Clinical Trials
• Product Description of Some of the Products in Preclinical and Early Phase I Stage
• ErythroMer
• Hemoglobin vesicles
• OxyVita
• OxyBridge

Chapter 10 Patent Analysis

• Introduction
• FDA Regulation
• FDA Good Manufacturing Practices and Reporting
• Patent Analysis

Chapter 11 Competitive Intelligence

• Strategic Developments
• Competitive Analysis

Chapter 12 Company Profiles

• AURUM BIOSCIENCES
• ERYPHARM
• HEMOGLOBIN OXYGEN THERAPEUTICS LLC.
• HEMARINA
• KALOCYTE INC.
• NANO SANGUIS S.A
• NUVOX PHARMA LLC.
• PROLONG PHARMACEUTICALS, LLC
• RED C BIOTECH
• VIRTECH BIO

List of Tables

• Summary Table : Global Market for Artificial Blood, Through 2028
• Table 1 : Historical Events Related to Blood Transfusion, 1628-2022
• Table 2 : Potential Benefits and Application Areas of Artificial Blood
• Table 3 : Average Number of Blood Units Required During Particular Medical Conditions
• Table 4 : The Challenges Associated with the Development of Artificial Blood
• Table 5 : Common Challenges to the Blood Transfusion Continuum in LMICs.
• Table 6 : Sources of Hemoglobin Molecules Used to Prepare Free Hemoglobin Solutions
• Table 7 : Pros and Cons of Artificial Blood Developed from Human Blood
• Table 8 : Pros and Cons of Artificial Blood Developed from Animal Blood
• Table 9 : Pros and Cons of Artificial Blood Developed from Recombinant Blood
• Table 10 : Summary of Acellular Hb-Based Oxygen Carriers
• Table 11 : Examples of Hemoglobin-based Oxygen Carrier Products and Approval Status
• Table 12 : Potential Clinical Applications of Oxygen Carriers
• Table 13 : Composition of PFC Emulsion-Based Artificial Blood Products
• Table 14 : First Generation Perfluorocarbon Emulsions Used in Medicine and Biology
• Table 15 : Comparative Study of Second-Generation PFCs
• Table 16 : PFC Emulsion Products and Current Status
• Table 17 : Comparative Study Between RBCs and HBOCs
• Table 18 : HBOC Solutions Transfusion: Side Effects and Possible Causes
• Table 19 : Examples of HBOC Products Developed, by Various Companies
• Table 20 : Global Market for Artificial Blood, Through 2028
• Table 21 : Current Cell Sources and Strategies for Ex-vivo RBC Generation
• Table 22 : List of Discontinued Blood Substitutes
• Table 23 : Hemopure: Raw Material and Method Overview
• Table 24 : Hemopure: Product Characteristics
• Table 25 : Hemopure: Advantages and Disadvantages
• Table 26 : Summary of Clinical Trials of Hemopure (HBOC-201), 2023
• Table 27 : HemO2life: Raw Material and Method
• Table 28 : HemO2life: Advantages and Disadvantages
• Table 29 : HemO2life: Product
• Table 30 : Ex vivo, In vivo and Clinical Studies involving HemO2life (M101) Use
• Table 31 : Hemotech: Raw Material and Method Overview
• Table 32 : HemoTech: Advantages and Disadvantages
• Table 33 : NanO2 (DDFPe): Raw Material and Method Overview
• Table 34 : NanO2 (DDFPe): Advantages and Disadvantages
• Table 35 : NanO2 (DDFPe): Clinical Trials, 2023
• Table 36 : Sanguinate: Raw Material and Method Overview
• Table 37 : Sanguinate: Advantages and Disadvantages
• Table 38 : Sanguinate: Clinical Trials, 2023
• Table 39 : Vidaphor: Raw Material and Method Overview
• Table 40 : Vidaphor: Advantages and Disadvantages
• Table 41 : Vidaphor: Clinical Trials, 2023

List of Figures

• Summary Figure : Global Market for Artificial Blood, 2020-2028
• Figure 1 : The Blood Continuum
• Figure 2 : Medical Use of Human Red Blood Cells in the U.S., 2019
• Figure 3 : Estimated Number of New Cancer Cases from 2020 to 2040
• Figure 4 : Discards of Blood Donations, by Reason, 2018
• Figure 5 : Artificial Blood Manufactured from Different Sources
• Figure 6 : History of HBOCs Developed Using Recombinant Technology
• Figure 7 : Classification of Modified Hemoglobin Solution Based on Methods
• Figure 8 : Classification of Different Types of Oxygen Carriers
• Figure 9 : Generations of Perfluorocarbon Emulsions
• Figure 10 : Advantages and Disadvantages of PFC Emulsions
• Figure 11 : Evolution of HBOCs
• Figure 12 : Advantages and Disadvantages of HBOCs
• Figure 13 : Global Potential Market for Artificial Blood, by Application, 2028
• Figure 14 : Biosynthetic RBC vs Artificial Blood Substitutes
• Figure 15 : Artificial Blood: Parameters for Product Analysis
• Figure 16 : Hemopure: Product Analysis
• Figure 17 : HemO2life: Product Analysis
• Figure 18 : NanO2 (DDFPe): Product Analysis
• Figure 19 : Sanguinate: Product Analysis
• Figure 20 : Current Competition in the Global Artificial Blood Market